-- This Week In The Money --

Analysis, Perspective, Trading Strategy

Is A Golden Age of Science Here?

Editor Joe Duarte in the Money Options

As each day passes, it becomes clear that we are at the Edge of Chaos, a place from where things emerge and complex adaptive systems, such as the Markets-Economy-Life (MEL) ecosystem move on to their next level of complexity, which is often a surprisingly positive development. Thus, as we head into a new decade, it makes sense to analyze the big picture, as we peek into The Edge of Chaos, the topic of my presentation at the February 2020 Money Show in Orlando.

After a volatile and politically contentious 2019, the new decade ahead will likely bring equally dramatic highs and lows. But regardless of the daily grind, and barring a major negative event, the potential for selective stock investors to deliver profits remains high. Moreover, even in a cautiously optimistic analysis it is important to keep an eye on where unexpected negative events that derail markets may come from. And while there are numerous members of a potential calamity list, here is a small sampling of plausible Black Swans whose occurrence would have well above average impact on MEL:

  • If he U.S.-China trade deal sours
  • If there are central bank policy errors
  • If a major liquidity crisis and/or bond market meltdown emerges
  • If events related to the U.S. election and the political situation in Washington reach a critical point which threatens the social order
  • A calamitous natural disaster of biblical proportions

Certainly, as the list above suggests, even as we look forward to what may be another profitable year, there is nothing wrong with keeping an eye out for potential problems and to act accordingly.

Why I’m Cautiously Optimistic

As 2019 wound down, I kept looking for reasons to sell stocks, but the act of selling wasn’t as easy as I thought it would be. Certainly, as I listed above, there is still plenty to worry about in the world, and any market analyst worth their salt will tell you that any day could be the start of a new bear market. But the usually wall of worry aside, as I wade through my equity charts on a daily basis, I am still finding a well above average number of stocks which seem to be at the point of nearing breakouts. All of which suggests that at this point, and until things change, it’s more about individual sectors and their components than about the worry.

Is 2020 the Year of the Turnaround Stock and Truly Meaningful Scientific Advances?

Perhaps the most interesting result of my recent analysis is how many companies in the midst of a corporate turnaround are starting to see positive results. One of them is Hewlett Packard (HPQ), a stodgy and long troubled PC and printer maker currently involved in a merger dispute with Xerox (XRX) whose endpoint is uncertain.



Interestingly, and well aside from the Xerox situation, HP shares seem to have bottomed and, may be knocking on the door of a potential chart breakout. And, if there is a breakout, it will likely come for good reasons, as margins are improving and revenues and earnings have started to climb as the company cuts costs and adapts to the current marketplace and re- invent their business via restructuring its operations through cutting management levels.

Indeed, the successful turnaround seems to be a trend that is gathering steam as companies look to increase efficiencies, reduce bureaucracy and speed the delivery of products from research to market and improve their competitiveness in an increasingly difficult environment. More specifically, HP is expanding its industrial and manufacturing presence via improved graphics platforms and via its 3D and digital manufacturing into areas such as automotive, as through its recent 3D parts manufacturing contract with Volkswagen, as it expands its product line to a more industrial base, while maintaining its still dominant PC and mainstream printer market share.



Encouragingly, the signs of new life and the possibility of critical mass being reached by turnaround companies are not just visible in the high tech industries. For example, in the pharmaceutical sector, the second half of the past decade delivered significant advances in the treatment of cancer. Yet, as I’ve written about multiple times recently, the future potential of the pharmaceuticals industry may be beyond even the most bullish expectations.

For instance, Pfizer (PFE) and Eli Lilly (LLY) are in late clinical trials for Tanezumab, a monoclonal antibody which blocks nerve growth factor, a chemical which is critical in the chronic pain generation pathway. Recent trials have been encouraging and the potential for FDA approval seems to be above average. Of course there are some potential roadblocks. For one, Tanezumab is not without risk, as there are reports of potentially serious side effects with its use.

But here is where the innovation kicks, perhaps turning Tanezumab into a blockbuster. If Pfizer and Lilly can make Tanezumab a safer drug, it will change the pharmaceutical landscape as it could significantly reduce the use of opioids over the next decade and beyond. Meanwhile, PFE recently submitted an application for Braftovi, its cancer drug, in combination therapy for colorectal cancer, while receiving a broadening of indications for Xtandi, its treatment resistant prostate cancer drug. In addition Pfizer has spun off its non prescription business and has a potential heart failure blockbuster drug in Vyndaqel. Lilly for its own part is making significant advances in the acute and chronic management of migraine headaches along with its recent advances in the treatment of certain types of leukemia and lymphoma while recently upgrading its earnings and revenue guidance for 2020.

My point is that in contrast to first decade of the 21 st century, where scientific advances – smart phones, social media, the commercialization of the Internet - were aimed at selling gadgets and what some may call trivial pursuits, we seem to be in the early stages of a period in which the implementation of truly meaningful scientific applications inside and outside of medicine may actually change the way we live and work at a different level than what we saw in the recent past.

Indeed, from an investing standpoint, it seems we may actually be in the early stages of a new golden age of science. And all things considered, that would not be a bad thing to see in the midst of all the ongoing uncertainty in this world.

New Highs all around

The New York Stock Exchange Advance Decline line (NYAD) continues to make new highs on a regular basis. And although the indicator is likely to pause at some point and investors should be prepared for a short term reversal, NYAD remains the most accurate indicator of the stock market’s trend, as it has been since the 2016 presidential election.



Interestingly, the bond market once again failed to reverse its recent downtrend fully, with the U.S. Ten Year note yield ending last week below 1.9% after threatening to move closer to 2% in the prior week. This remains a positive for the overall trend in the market, as a move above 2% on TNX would be unpredictable for the markets.



Meanwhile, the new highs on NYAD have been confirmed by new highs on the Nasdaq 100 (NDX) and the S & P 500 (SPX) indexes, suggesting that the trend for stocks remains up.



As a result, taking some profits before the end of the year is not a bad idea.

Rotate Portfolios into turn around Stocks in the New Year

I am having no trouble finding stocks with positive money flows whose prices seem ready to break out. In fact, there are quite a number of companies whose recent restructurings may be ready to bear fruit.

Thus as we head into the 2020 and the start of new decade, it makes sense to rearrange portfolios in order to accommodate new picks. Moreover, investors who fight greed and take some profits while simultaneously deploying them into stocks that have not had big runs of late, but seem poised to do so are likely to do better as 2020 progresses.

Happy New Year

I own PFE, LLY, and HPQ as of this writing.

Joe Duarte is a former money manager, an active trader and a widely recognized independent stock market analyst since 1987. He is author of eight investment books, including the best sellingTrading Options for Dummies, rated a TOP Options Book for 2018 by Benzinga.com - now in its third edition, The Everything Investing in your 20s and 30s and six other trading books.

Meanwhile, the U.S. Ten Year note yield (TNX) is trading in a The Everything Investing in your 20s & 30s at Amazon and The Everything Investing in your 20s & 30s at Barnes and Noble.

A Washington Post Color of Money Book of the Month is now available.

To receive Joe’s exclusive stock, option, and ETF recommendations, in your mailbox every week visit https://joeduarteinthemoneyoptions.com/secure/order_email.asp.


JoeDuarteInTheMoneyOptions.com is independently operated and solely funded by subscriber fees. This web site and the content provided is meant for educational purposes only and is not a solicitation to buy or sell any securities or investments. All sources of information are believed to be accurate, or as otherwise stated. Dr. Duarte and the publishers, partners, and staff of joeduarteinthemoneyoptions.com have no financial interest in any of the sources used. For independent investment advice consult your financial advisor. The analysis and conclusions reached on JoeDuarteInTheMoneyOptions.com are the sole property of Dr. Joe Duarte.